These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 9341921

  • 1. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
    Anizon F, Belin L, Moreau P, Sancelme M, Voldoire A, Prudhomme M, Ollier M, Sevère D, Riou JF, Bailly C, Fabbro D, Meyer T.
    J Med Chem; 1997 Oct 10; 40(21):3456-65. PubMed ID: 9341921
    [Abstract] [Full Text] [Related]

  • 2. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle.
    Moreau P, Anizon F, Sancelme M, Prudhomme M, Bailly C, Carrasco C, Ollier M, Sevère D, Riou JF, Fabbro D, Meyer T, Aubertin AM.
    J Med Chem; 1998 May 07; 41(10):1631-40. PubMed ID: 9572888
    [Abstract] [Full Text] [Related]

  • 3. Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties.
    Pereira ER, Belin L, Sancelme M, Prudhomme M, Ollier M, Rapp M, Sevère D, Riou JF, Fabbro D, Meyer T.
    J Med Chem; 1996 Oct 25; 39(22):4471-7. PubMed ID: 8893841
    [Abstract] [Full Text] [Related]

  • 4. Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent.
    Moreau P, Anizon F, Sancelme M, Prudhomme M, Bailly C, Sevère D, Riou JF, Fabbro D, Meyer T, Aubertin AM.
    J Med Chem; 1999 Feb 25; 42(4):584-92. PubMed ID: 10052965
    [Abstract] [Full Text] [Related]

  • 5. Synthesis, mode of action, and biological activities of rebeccamycin bromo derivatives.
    Moreau P, Anizon F, Sancelme M, Prudhomme M, Sevère D, Riou JF, Goossens JF, Hénichart JP, Bailly C, Labourier E, Tazzi J, Fabbro D, Meyer T, Aubertin AM.
    J Med Chem; 1999 May 20; 42(10):1816-22. PubMed ID: 10346933
    [Abstract] [Full Text] [Related]

  • 6. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
    Bailly C, Riou JF, Colson P, Houssier C, Rodrigues-Pereira E, Prudhomme M.
    Biochemistry; 1997 Apr 01; 36(13):3917-29. PubMed ID: 9092822
    [Abstract] [Full Text] [Related]

  • 7. Syntheses and antiproliferative activities of 7-azarebeccamycin analogues bearing one 7-azaindole moiety.
    Marminon C, Pierré A, Pfeiffer B, Pérez V, Léonce S, Joubert A, Bailly C, Renard P, Hickman J, Prudhomme M.
    J Med Chem; 2003 Feb 13; 46(4):609-22. PubMed ID: 12570382
    [Abstract] [Full Text] [Related]

  • 8. Indolocarbazole glycosides in inactive conformations.
    Facompré M, Carrasco C, Vezin H, Chisholm JD, Yoburn JC, Van Vranken DL, Bailly C.
    Chembiochem; 2003 May 09; 4(5):386-95. PubMed ID: 12740810
    [Abstract] [Full Text] [Related]

  • 9. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
    Bailly C, Qu X, Chaires JB, Colson P, Houssier C, Ohkubo M, Nishimura S, Yoshinari T.
    J Med Chem; 1999 Jul 29; 42(15):2927-35. PubMed ID: 10425102
    [Abstract] [Full Text] [Related]

  • 10. Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition.
    Bailly C, Qu X, Graves DE, Prudhomme M, Chaires JB.
    Chem Biol; 1999 May 29; 6(5):277-86. PubMed ID: 10322124
    [Abstract] [Full Text] [Related]

  • 11. Syntheses and biological activities of rebeccamycin analogues with uncommon sugars.
    Zhang G, Shen J, Cheng H, Zhu L, Fang L, Luo S, Muller MT, Lee GE, Wei L, Du Y, Sun D, Wang PG.
    J Med Chem; 2005 Apr 07; 48(7):2600-11. PubMed ID: 15801850
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and biological activities of indolocarbazoles bearing amino acid residues.
    Moreau P, Sancelme M, Bailly C, Léonce S, Pierré A, Hickman J, Pfeiffer B, Prudhomme M.
    Eur J Med Chem; 2001 Apr 07; 36(11-12):887-97. PubMed ID: 11755231
    [Abstract] [Full Text] [Related]

  • 13. Syntheses, biochemical and biological evaluation of staurosporine analogues from the microbial metabolite rebeccamycin.
    Anizon F, Moreau P, Sancelme M, Voldoire A, Prudhomme M, Ollier M, Sevère D, Riou JF, Bailly C, Fabbro D, Meyer T, Aubertin AM.
    Bioorg Med Chem; 1998 Sep 07; 6(9):1597-604. PubMed ID: 9801830
    [Abstract] [Full Text] [Related]

  • 14. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
    Bailly C, Carrasco C, Hamy F, Vezin H, Prudhomme M, Saleem A, Rubin E.
    Biochemistry; 1999 Jul 06; 38(27):8605-11. PubMed ID: 10393535
    [Abstract] [Full Text] [Related]

  • 15. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
    Riou JF, Fossé P, Nguyen CH, Larsen AK, Bissery MC, Grondard L, Saucier JM, Bisagni E, Lavelle F.
    Cancer Res; 1993 Dec 15; 53(24):5987-93. PubMed ID: 8261412
    [Abstract] [Full Text] [Related]

  • 16. DNA binding properties of the indolocarbazole antitumor drug NB-506.
    Carrasco C, Vezin H, Wilson WD, Ren J, Chaires JB, Bailly C.
    Anticancer Drug Des; 2001 Dec 15; 16(2-3):99-107. PubMed ID: 11962518
    [Abstract] [Full Text] [Related]

  • 17. A DNA binding indolocarbazole disaccharide derivative remains highly cytotoxic without inhibiting topoisomerase I.
    Qu X, Chaires JB, Ohkubo M, Yoshinari T, Nishimura S, Bailly C.
    Anticancer Drug Des; 1999 Oct 15; 14(5):433-42. PubMed ID: 10766298
    [Abstract] [Full Text] [Related]

  • 18. Syntheses and antiproliferative activities of rebeccamycin analogues bearing two 7-azaindole moieties.
    Marminon C, Pierré A, Pfeiffer B, Pérez V, Léonce S, Renard P, Prudhomme M.
    Bioorg Med Chem; 2003 Mar 06; 11(5):679-87. PubMed ID: 12537997
    [Abstract] [Full Text] [Related]

  • 19. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
    Gamage SA, Spicer JA, Atwell GJ, Finlay GJ, Baguley BC, Denny WA.
    J Med Chem; 1999 Jul 01; 42(13):2383-93. PubMed ID: 10395479
    [Abstract] [Full Text] [Related]

  • 20. Recent developments of rebeccamycin analogues as topoisomerase I inhibitors and antitumor agents.
    Prudhomme M.
    Curr Med Chem; 2000 Dec 01; 7(12):1189-212. PubMed ID: 11032967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.